Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | UQCRB | P14927 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM6A | O15550 | 1/20 | 0.40 |
| ▸ | TET3 | O43151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133560 | 0.90 | KDM4E (0.54) | TDP1METAP1KDM4EIDO1PDE4D | |
| SCHEMBL18216600 | 0.84 | SLC40A1 (0.51) | KMT2AMEN1METAP1LMNAHTT | |
| SCHEMBL367901 | 0.80 | IDO1 (0.54) | KMT2AMEN1IDO1NPC1RAB9A | |
| SCHEMBL29662262 | 0.80 | IDO1 (0.54) | KMT2AMEN1IDO1NPC1RAB9A | |
| SCHEMBL22556188 | 0.80 | TDP1 (0.61) | KMT2AMEN1TDP1METAP1KDM4E | |
| SCHEMBL13667124 | 0.78 | METAP1 (0.41) | KMT2AMEN1METAP1KDM4EPDE4D | |
| SCHEMBL2392457 | 0.77 | METAP1 (0.56) | KMT2AMEN1METAP1LMNARAB9A | |
| SCHEMBL17981261 | 0.77 | METAP1 (0.53) | KMT2AMEN1METAP1NPC1RAB9A | |
| SCHEMBL12790198 | 0.77 | HTT (0.41) | KMT2AMEN1METAP1PDE4DHTT | |
| SCHEMBL116767 | 0.76 | MEN1 (0.65) | KMT2AMEN1METAP1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285805-B1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2285805-B1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| CN-102066371-A | Aryl-quinolyl compounds and their use | CANCER REC TECH LTD | 2011-05-18 | — | — | CN | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| EP-2285805-A1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009130487-A1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130487-A1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | KMT2A 1119/4885MEN1 3448/4885PKM 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.